EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Induction Cisplatin, Docetaxel, and 5-Fluorouracil Versus Platinum Doublet in Human Papillomavirus-Associated Oropharyngeal Cancer

Ashwin Ganti iD, Patrick W McGarrah iD, Harry Fuentes Bayne iD, Casey Fazer-Posorske, Binav Baral iD, Daniel J Ma iD, Scott C Lester, David M Routman, Michelle A Neben-Wittich, Jessica M Wilson iD, Daniel L Price, Eric J Moore und 5 weitere

Viruses · 08.04.2026 · 18 (4) · 446

DOI: 10.3390/v18040446 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, online erschienen am 08.04.2026. Verfasst von Ashwin Ganti und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, University of California San Diego, San Diego, CA 92037, USA. Hauptthemen laut MEDLINE: Oropharyngeal Neoplasms, Fluorouracil, Cisplatin, Docetaxel. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Management of locoregionally advanced human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV(+) OPSCC) can include induction chemotherapy followed by definitive chemoradiation. The standard induction regimen of cisplatin, docetaxel, and 5-fluorouracil (TPF) is associated with high toxicity. Given the chemosensitivity of HPV(+) OPSCC, platinum doublets are frequently used as induction therapy with potentially less toxicity. This retrospective study aimed to compare outcomes between treatment-naive HPV(+) OPSCC patients receiving induction TPF and those receiving an induction platinum doublet. Data collected included tumor characteristics, response after chemoradiation, hospitalization rates, and overall survival (OS). Fifty-five patients (18 TPF and 37 platinum doublet) were included. There was no significant difference in response after completion of definitive chemoradiation (TPF: CR 83.3%, PR 5.6%, progression or metastasis 11.1% vs. platinum doublet: CR 75.7%, PR 16.2%, progression or metastasis 8.1%; p = 0.5241). There were also no differences in hospitalizations for adverse events (38.9% in TPF vs. 40.5% in platinum doublet, p = 0.907) or recurrence (11.1% in TPF vs. 2.7% in platinum doublet, p = 0.198). The 5-year OS was 84.6% in the TPF group and 81.5% in the platinum doublet group (p = 0.581). Induction platinum doublet regimens offer comparable OS, response, and hospitalization rates to TPF in locally advanced HPV(+) OPSCC. Induction with a platinum doublet may be a viable de-escalation strategy for patients who are not candidates for TPF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oropharyngeal NeoplasmsFluorouracilCisplatinDocetaxelPapillomavirus InfectionsAntineoplastic Combined Chemotherapy ProtocolsPlatinumHumansFemaleRetrospective StudiesMiddle AgedMaleHuman Papillomavirus VirusesAgedInduction ChemotherapyTreatment OutcomePapillomaviridaeAdultChemoradiotherapyCarcinoma, Squamous Cell

Stichwörter der Autor:innen

HPVde-escalationhuman papillomavirusinduction chemotherapyoropharyngeal canceroropharynx cancerplatinum doublet

Substanzen

FluorouracilCisplatinDocetaxelPlatinum

Autor:innen und Institutionen

  • Division of Hematology-Oncology, University of California San Diego, San Diego, CA 92037, USA.
  • Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.
  • Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, Rochester, MN 55905, USA.
  • Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN 55905, USA.

ORCID-Profile: Ashwin Ganti, Patrick W McGarrah, Harry Fuentes Bayne, Binav Baral, Daniel J Ma, Jessica M Wilson, Katharine Price

Zitieren

APA

Ganti, A., McGarrah, P. W., Fuentes Bayne, H., Fazer-Posorske, C., Baral, B., Ma, D. J., Lester, S. C., Routman, D. M., Neben-Wittich, M. A., Wilson, J. M., Price, D. L., Moore, E. J., Tasche, K. K., Van Abel, K. M., Yin, L. X., Foster, N. R., & Price, K. (2026). Induction Cisplatin, Docetaxel, and 5-Fluorouracil Versus Platinum Doublet in Human Papillomavirus-Associated Oropharyngeal Cancer. Viruses, 18(4), 446. https://doi.org/10.3390/v18040446

Vancouver

Ganti A, McGarrah PW, Fuentes Bayne H, Fazer-Posorske C, Baral B, Ma DJ, et al. Induction Cisplatin, Docetaxel, and 5-Fluorouracil Versus Platinum Doublet in Human Papillomavirus-Associated Oropharyngeal Cancer. Viruses. 2026;18(4):446. doi:10.3390/v18040446

BibTeX
@article{Ganti2026,
  author = {Ganti, Ashwin and McGarrah, Patrick W and Fuentes Bayne, Harry and Fazer-Posorske, Casey and Baral, Binav and Ma, Daniel J and Lester, Scott C and Routman, David M and Neben-Wittich, Michelle A and Wilson, Jessica M and Price, Daniel L and Moore, Eric J and Tasche, Kendall K and Van Abel, Katie M and Yin, Linda X and Foster, Nathan R and Price, Katharine},
  title = {Induction Cisplatin, Docetaxel, and 5-Fluorouracil Versus Platinum Doublet in Human Papillomavirus-Associated Oropharyngeal Cancer},
  journal = {Viruses},
  year = {2026},
  volume = {18},
  number = {4},
  pages = {446},
  doi = {10.3390/v18040446}
}
Kostenlos starten →